Uploaded October 2026 | Updated November 2026, 2 days ago
Drs Lisa VanWagner and Kathleen Corey examine how MASLD should shape cardiovascular risk assessment, statin use, and treatment decisions.
Relevant disclosures can be found with the episode show notes on Medscape medscape.com/ca8/p04/podcast-masld-s1-ep6-2026a1000aay. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5
Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiovascular Disease pubmed.ncbi.nlm.nih.gov/41124780
FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis
Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease pubmed.ncbi.nlm.nih.gov/32707340
Non-Alcoholic Fatty Liver Disease and Risk of Fatal and Non-Fatal Cardiovascular Events: An Updated Systematic Review and Meta-Analysis pubmed.ncbi.nlm.nih.gov/34555346
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association pubmed.ncbi.nlm.nih.gov/37807924
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines pubmed.ncbi.nlm.nih.gov/41824552
CVD Risk Estimator Plus tools.acc.org/cvd-risk-estimator-plus/#!/calculate/estimate
Role of Coronary Artery Calcium Testing for Risk Assessment in Primary Prevention of Atherosclerotic Cardiovascular Disease: A Review pubmed.ncbi.nlm.nih.gov/34613362
Risk-Associated and Clinically Informative Biomarkers for Cardiovascular Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease pubmed.ncbi.nlm.nih.gov/41624044
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein pubmed.ncbi.nlm.nih.gov/18997196
Statin Liver Safety in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Metanalysis pubmed.ncbi.nlm.nih.gov/34133035
Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance pubmed.ncbi.nlm.nih.gov/39422487
Effect of Non-Statin Lipid-Lowering Therapy on Hepatic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review pubmed.ncbi.nlm.nih.gov/41048606
The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective pubmed.ncbi.nlm.nih.gov/24084292
The Role of FibroScan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease pmc.ncbi.nlm.nih.gov/articles/PMC10209980
Transcatheter Left Atrial Appendage Closure: Devices Available, Pitfalls, Advantages, and Future Directions pubmed.ncbi.nlm.nih.gov/39493945
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Drs Lisa VanWagner and Kathleen Corey examine how MASLD should shape cardiovascular risk assessment, statin use, and treatment decisions.
Relevant disclosures can be found with the episode show notes on Medscape medscape.com/ca8/p04/podcast-masld-s1-ep6-2026a1000aay. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5
Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiovascular Disease pubmed.ncbi.nlm.nih.gov/41124780
FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis
Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease pubmed.ncbi.nlm.nih.gov/32707340
Non-Alcoholic Fatty Liver Disease and Risk of Fatal and Non-Fatal Cardiovascular Events: An Updated Systematic Review and Meta-Analysis pubmed.ncbi.nlm.nih.gov/34555346
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association pubmed.ncbi.nlm.nih.gov/37807924
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines pubmed.ncbi.nlm.nih.gov/41824552
CVD Risk Estimator Plus tools.acc.org/cvd-risk-estimator-plus/#!/calculate/estimate
Role of Coronary Artery Calcium Testing for Risk Assessment in Primary Prevention of Atherosclerotic Cardiovascular Disease: A Review pubmed.ncbi.nlm.nih.gov/34613362
Risk-Associated and Clinically Informative Biomarkers for Cardiovascular Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease pubmed.ncbi.nlm.nih.gov/41624044
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein pubmed.ncbi.nlm.nih.gov/18997196
Statin Liver Safety in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Metanalysis pubmed.ncbi.nlm.nih.gov/34133035
Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance pubmed.ncbi.nlm.nih.gov/39422487
Effect of Non-Statin Lipid-Lowering Therapy on Hepatic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review pubmed.ncbi.nlm.nih.gov/41048606
The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective pubmed.ncbi.nlm.nih.gov/24084292
The Role of FibroScan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease pmc.ncbi.nlm.nih.gov/articles/PMC10209980
Transcatheter Left Atrial Appendage Closure: Devices Available, Pitfalls, Advantages, and Future Directions pubmed.ncbi.nlm.nih.gov/39493945
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.










